Alto Neuroscience, Inc. (ANRO) stock
ANRONYSEPharmaceutical PreparationsFiscal year ends December 31
$27.12−2.42 (-8.19%)
Close on Nov 16, 2026Market cap $1.06BP/E –Yield –
Earnings
Alto Neuroscience's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Mar 15, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
-$0.54
-$0.52 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Alto Neuroscience's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 15, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 10, 2026after the close | – | – | -$0.54 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 12, 2026after the close | – | – | -$0.65 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 13, 2026before the open | – | – | -$0.80 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 16, 2026before the open | – | – | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 12, 2025before the open | – | – | -$0.52 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 13, 2025after the close | – | – | – | Release |
| Q1 FY2025ended Mar 31, 2025 | May 14, 2025after the close | – | – | -$0.56 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 20, 2025after the close | – | – | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 12, 2024after the close | – | – | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 13, 2024after the close | – | – | -$0.60 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 14, 2024after the close | – | – | -$0.76 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 21, 2024after the close | – | – | – | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Alto Neuroscience has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Alto Neuroscience puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Alto Neuroscience filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- News
- News
- Results
- Results
- News
- News
- Results
- News
- News
- Results
- Results
- News
See a number that looks wrong?